myotwin GmbH looks back on a successful debut at SLUSH 2025 in Helsinki. The international investor conference provided an ideal setting to present the company’s technology platform to a broad audience of investors and innovation stakeholders, while offering first insights into current developments.
On site, myotwin was represented by co-founders Dr. Jan Pietras and Andreas Meyer-Borgstädt. In numerous conversations, they showcased recent advances in human tissue models and digital heart simulations and engaged with potential partners from research, industry, and investment. The dedicated biotech sessions at SLUSH enabled focused exchanges with key representatives from the life sciences and […]
myotwin GmbH looks back on a successful participation at BIO-Europe 2025 in Vienna. For the third time, the company was represented at Europe’s most important partnering conference for the biotech and pharmaceutical industry. From November 3–5, experts from across Europe gathered to discuss current developments and emerging therapeutic approaches.
For myotwin, BIO-Europe once again provided a valuable opportunity to showcase the latest advancements in human tissue models and digital cardiac simulations. Particularly encouraging was the strong interest in reliable, human-relevant data for cardiovascular drug development, a key topic in many conversations and a clear indication of the growing importance of this approach within the […]
myotwin GmbH looks back on a successful first appearance at ELRIG Drug Discovery 2025 in Liverpool. The event offered the young company an excellent opportunity to present its work to a new scientific audience and to gather relevant insights for cardiovascular research.
Co-founder and COO Dr. Jan Pietas attended the conference and presented the poster “Decoding the Human Heart”, which provided a structured overview of the myotwin platform and its application in preclinical drug development. The subsequent discussions led to an intensive scientific exchange with experts from various areas of drug discovery. Feedback regarding the value of human-based […]
As of August 1, myotwin GmbH has expanded its presence by moving into office space at the Rechtsrheinisches Technologie- und Gründerzentrum Cologne (RTZ). With this step, the biotech start-up continues to grow its business activities while strengthening its integration into Cologne’s high-tech ecosystem.
The RTZ provides young technology companies in their early stages with office and laboratory space, fully equipped seminar and meeting rooms, business support services, and access to an extensive network. As an incubator, it helps founders bring their ideas to life and lays the foundation for sustainable growth. Currently, around 40 companies form a vibrant […]
For the second time, myotwin GmbH participated in the BIO International Convention, the world’s largest trade fair for biotechnology and pharmaceuticals.
For the myotwin team, the convention was more than just an industry gathering – it was a valuable opportunity to present its technology platform for the development of new cardiovascular therapeutics on an international stage and to further expand its network. The focus was on intensive discussions with potential partners from pharma and biotech – […]
myotwin GmbH looks back on a successful participation at this year’s International MPS Society (iMPSS) conference in Brussels.
The international forum, organized by EUROoCS and the International MPS Society, brought together leading scientists, industry representatives, and patient groups to discuss the latest developments in mucopolysaccharidosis (MPS) and related diseases. A particular highlight was myotwin’s poster presentation “Heart Attack in a Dish.” The model, which replicates cardiovascular disease mechanisms at the cellular level, attracted […]
The biotech start-up myotwin GmbH has successfully completed the EXIST Research Transferprogram. With funding from the Federal Ministry for Economic Affairs and Energy (BMWE), the foundation for the company spin-off was established and its technology platform significantly advanced.
Following the completion of Phase I (Sept. 2022–Aug. 2024), carried out by the University Medical Center Göttingen, Phase II was implemented by myotwin GmbH and ran until the end of March 2025. “We are very grateful for the support provided through the EXIST Research Transfer. It paved the way for us to bring our technology […]
The biotech start-up myotwin GmbH and the data management company IndiScale GmbH are launching a joint project to optimize the production of artificially generated human mini-organs using artificial intelligence.
Artificial Organs for Heart Research The artificial production of heart muscle tissue offers a promising approach for the development of new drugs against cardiovascular diseases, which are the leading cause of death worldwide. The project “AI-based Optimization of the Production of Cardiac Bodies” aims to make the production process of Cardiac Bodies – a precursor […]
Three days filled with discussions, meetings, and fresh inspiration: myotwin GmbH took part in BIO-Europe Spring 2025 in Milan and draws a thoroughly positive conclusion. The conference is one of the leading meeting points for the European biotech and pharma community and once again offered a dynamic environment for exchange and collaboration.
For the myotwin team, networking with industry partners was at the forefront. Numerous encounters with representatives from both industry and the start-up scene opened up new perspectives and confirmed myotwin’s growing role within the international biotech ecosystem. A particular highlight was reconnecting with colleagues from the EXIST funding program, including the team from immuneAdvice GmbH. […]
myotwin GmbH has successfully completed the HTI funding program of the State of Lower Saxony. The €200,000 funding project was coordinated through the Life Science Valley in Göttingen and enabled myotwin to successfully launch its business operations.
With the funding, the company was able to establish laboratory infrastructure in the Life Science Factory in Göttingen, hire its first scientific staff, and validate key technologies for the planned platform. This laid the foundation for preparing initial pilot studies with partners from the pharmaceutical and biotech industries and paved the way for market entry. […]